NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55111-0153-78 | 55111-0153 | Ondansetron Hydrochloride | ONDANSETRON | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
50090-1200-03 | 50090-1200 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 17, 2017 | In Use | |
55111-0154-13 | 55111-0154 | Ondansetron Hydrochloride | ONDANSETRON | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
80425-0073-02 | 80425-0073 | Ondansetron, Ondansetron OD 4mg | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 12, 2010 | In Use | |
00173-0569-00 | 00173-0569 | Ondansetron Hydrochloride | Zofran ODT | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 1, 1999 | Sep 30, 2017 | No Longer Used |
00641-6079-01 | 00641-6079 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 26, 2006 | In Use | |
55390-0121-01 | 55390-0121 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 26, 2006 | Jul 31, 2012 | No Longer Used | |
52125-0744-08 | 52125-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jan 6, 2014 | Apr 14, 2016 | No Longer Used | |
69097-0195-67 | 69097-0195 | Granisetron Hydrochloride | Granisetron Hydrochloride | 0.1 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Dec 31, 2007 | Apr 30, 2020 | No Longer Used |
83008-0026-65 | 83008-0026 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 3, 2023 | Mar 31, 2026 | In Use |
70518-4245-00 | 70518-4245 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 20, 2024 | In Use | |
43598-0671-11 | 43598-0671 | Fosaprepitant | Fosaprepitant | 150.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Mar 20, 2020 | In Use | |
00093-7302-03 | 00093-7302 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 23, 2010 | Nov 30, 2012 | No Longer Used | |
51672-4109-08 | 51672-4109 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 28, 2011 | In Use | |
54348-0821-00 | 54348-0821 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 8, 2019 | In Use | |
67877-0754-60 | 67877-0754 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Mar 3, 2021 | In Use | |
69452-0350-11 | 69452-0350 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 28, 2022 | In Use | |
83980-0013-10 | 83980-0013 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 19, 2025 | In Use | |
51662-1367-01 | 51662-1367 | Metoclopramide | Metoclopramide | 10.0 mg/2mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Oct 14, 2019 | In Use | |
55111-0154-01 | 55111-0154 | Ondansetron Hydrochloride | ONDANSETRON | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
68071-2969-03 | 68071-2969 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 6, 2023 | In Use | |
33261-0417-20 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
51407-0701-05 | 51407-0701 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Jun 11, 2025 | In Use | |
33261-0417-06 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
23155-0549-31 | 23155-0549 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jun 15, 2012 | In Use |
Found 11765 results — Export these results